1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Medicis Pharmaceutical Corporation - Product Pipeline Review - 2013

Medicis Pharmaceutical Corporation - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 27 pages

Medicis Pharmaceutical Corporation - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Medicis Pharmaceutical Corporation - Product Pipeline Review - 2013” provides data on the Medicis Pharmaceutical Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Medicis Pharmaceutical Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Medicis Pharmaceutical Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Medicis Pharmaceutical Corporation - Brief Medicis Pharmaceutical Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Medicis Pharmaceutical Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Medicis Pharmaceutical Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Medicis Pharmaceutical Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Medicis Pharmaceutical Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Medicis Pharmaceutical Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Medicis Pharmaceutical Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Medicis Pharmaceutical Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Medicis Pharmaceutical Corporation and identify potential opportunities in those areas.

Table Of Contents

Medicis Pharmaceutical Corporation - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Medicis Pharmaceutical Corporation Snapshot 4
Medicis Pharmaceutical Corporation Overview 4
Key Information 4
Key Facts 4
Medicis Pharmaceutical Corporation - Research and Development Overview 5
Key Therapeutic Areas 5
Medicis Pharmaceutical Corporation - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Medicis Pharmaceutical Corporation - Pipeline Products Glance 9
Medicis Pharmaceutical Corporation - Late Stage Pipeline 9
Phase III Products/Combination Treatment Modalities 9
Medicis Pharmaceutical Corporation Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Medicis Pharmaceutical Corporation - Drug Profiles 11
CB-03-01 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Product-10156 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Product-49778 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Product-55394 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Medicis Pharmaceutical Corporation - Pipeline Analysis 15
Medicis Pharmaceutical Corporation - Pipeline Products by Therapeutic Class 15
Medicis Pharmaceutical Corporation - Pipeline Products By Target 16
Medicis Pharmaceutical Corporation - Pipeline Products by Route of Administration 17
Medicis Pharmaceutical Corporation - Pipeline Products By Mechanism of Action 18
Medicis Pharmaceutical Corporation - Recent Pipeline Updates 19
Medicis Pharmaceutical Corporation - Dormant Projects 21
Medicis Pharmaceutical Corporation - Company Statement 22
Medicis Pharmaceutical Corporation - Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Tables

Medicis Pharmaceutical Corporation, Key Information 4
Medicis Pharmaceutical Corporation, Key Facts 4
Medicis Pharmaceutical Corporation - Pipeline by Indication, 2013 6
Medicis Pharmaceutical Corporation - Pipeline by Stage of Development, 2013 7
Medicis Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2013 8
Medicis Pharmaceutical Corporation - Phase III, 2013 9
Medicis Pharmaceutical Corporation - Phase II, 2013 10
Medicis Pharmaceutical Corporation - Pipeline By Therapeutic Class, 2013 15
Medicis Pharmaceutical Corporation - Pipeline By Target, 2013 16
Medicis Pharmaceutical Corporation - Pipeline By Route of Administration, 2013 17
Medicis Pharmaceutical Corporation - Pipeline Products By Mechanism of Action, 2013 18
Medicis Pharmaceutical Corporation - Recent Pipeline Updates, 2013 19
Medicis Pharmaceutical Corporation - Dormant Developmental Projects,2013 21
Medicis Pharmaceutical Corporation, Subsidiaries 24

List of Figures

Medicis Pharmaceutical Corporation - Pipeline by Indication, 2013 6
Medicis Pharmaceutical Corporation - Pipeline by Stage of Development, 2013 7
Medicis Pharmaceutical Corporation - Monotherapy Products in Pipeline, 2013 8
Medicis Pharmaceutical Corporation - Pipeline By Therapeutic Class, 2013 15
Medicis Pharmaceutical Corporation - Pipeline By Route of Administration, 2013 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.